Thomas Noesslinger

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth, Tea Pemovska, Gregory I. Vladimer et al. · Cancer Discovery · 2021 · 196 citations · Full text

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

Mar Mallo, José Cervera, Julie Schanz et al. · Leukemia · 2010 · 120 citations · Full text

Hematological Malignancy, Deletion 5Q, Myelodysplastic Syndrome +6

Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes

Friedrich Wimazal, Ulrich Germing, Michael Kundi et al. · Cancer · 2010 · 60 citations

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · Blood · 2021 · 33 citations

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d’Amore, Sirpa Leppä, María Gomes da Silva et al. · Blood · 2018 · 26 citations